ELOX · TickerCove

ELOXEloxx Pharmaceuticals, Inc.Healthcare · Biotechnologyas of 2026-09-25

Horizon

Issued 2026-09-25 at $15.03 · now $15.03 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, ELOX has typically landed between $6.92 and $33.61 — a range of −53.9% to +123.6% from the issuance price $15.03.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

4,951 overlapping 1 month windows · 2006-09-26 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($15.03) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$15.03 · 72% of range

$0 low$20.98 high

Trailing 52 weeks to 2026-09-25 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,391 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.7%

90% CI 51.5%–55.9%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−10.2%

typical move · IQR 41.2%

−53.9%worst (p90)+123.6%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where ELOX has typically landed a month from the 2026-09-25 close of $15.03 — the range is history, not a prediction.

now $15.03 (+0.0%)
typical $13.49 (-10.2%)
middle 50% $10.4–$16.59
90% range $6.92–$33.61

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,951 windows spanning 2006-09-26 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2024-08-22	−100.0%	−100.0%	+0.0%
2024-08-27	−100.0%	−100.0%	+0.0%
2024-08-28	−100.0%	−100.0%	+0.0%
3 best
2026-05-13	+571328.6%	+0.0%	+699900.0%
2026-05-14	+559423.8%	+0.0%	+699900.0%
2026-02-26	+189900.0%	+0.0%	+189900.0%

4,951 overlapping windows · 2006-09-26 – 2026-09-25 · not cherry-picked

Pending catalysts

2027-06-30 — Trial primary completion: Phase 2 primary completion: EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

25%

−10.6%

n=20

Feb

50%

+0.8%

n=20

Mar

35%

+4035.3%

n=20

Apr

50%

+19.0%

n=20

May

45%

+107.8%

n=20

Jun

40%

+9.6%

n=20

Jul

25%

−4.8%

n=20

Aug

40%

+2.2%

n=20

Sep

20%

−14.0%

n=20

Oct

25%

−19.8%

n=20

Nov

50%

−0.5%

n=20

Dec

45%

+49996.7%

n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

67 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-06-10	Aggarwal Sumit	director	Award / grant	328,833	328,833	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	238,422	0	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	361,578	361,578	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	361,578	834,489	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	238,422	238,422	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	361,578	361,578	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	238,422	0	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	361,578	834,489	Form 4
2026-06-10	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	238,422	238,422	Form 4
2026-06-08	Walts Alan Edmund	director	Award / grant	8,590	8,590	Form 4
2026-06-08	Rubin Steven D	director	Award / grant	4,018	4,018	Form 4
2026-06-08	Kjellson Nina S	director	Award / grant	13,587	13,587	Form 4
2026-06-08	Webster Stephen W	director	Award / grant	13,587	13,587	Form 4
2026-05-27	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	113,636	0	Form 4
2026-05-27	Coastlands Capital LP	tenPercentOwner	Other acquisition	1,250,000	0	Form 4
2026-05-27	Coastlands Capital LP	tenPercentOwner	Other acquisition	1,250,000	30,612,243	Form 4
2026-05-27	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	113,636	238,422	Form 4
2026-05-27	Domicilium Real Estate Fund III LP	tenPercentOwner	Other acquisition	113,636	238,422	Form 4
2026-02-28	Aggarwal Sumit	director	Option exercise	260,946	1,672,756	Form 4
2026-02-28	Aggarwal Sumit	director	Option exercise	260,946	3,336,144	Form 4
2026-01-24	Rubin Steven D	director	Option exercise	1,875	1,875	Form 4
2026-01-24	Walts Alan Edmund	director	Option exercise	1,875	1,875	Form 4
2026-01-24	Aggarwal Sumit	director	Option exercise	15,000	15,000	Form 4
2026-01-24	Walts Alan Edmund	director	Option exercise	1,875	15,567	Form 4
2026-01-24	Walts Alan Edmund	director	Option exercise	1,875	15,567	Form 4
2026-01-24	Aggarwal Sumit	director	Option exercise	15,000	1,411,810	Form 4
2026-01-24	Rubin Steven D	director	Option exercise	1,875	14,625	Form 4
2026-01-24	Rubin Steven D	director	Option exercise	1,875	14,625	Form 4
2026-01-24	Aggarwal Sumit	director	Option exercise	15,000	1,411,810	Form 4
2025-09-19	Rubin Steven D	director	Award / grant	179,854	179,854	Form 4
2025-09-19	Walts Alan Edmund	director	Award / grant	395,680	395,680	Form 4
2025-09-19	Aggarwal Sumit	director	Award / grant	1,000,000	1,396,810	Form 4
2025-09-19	Aggarwal Sumit	director	Award / grant	3,597,090	3,597,090	Form 4
2025-08-14	Aggarwal Sumit	director	Option exercise	196,880	396,810	Form 4
2025-08-14	Aggarwal Sumit	director	Option exercise	42,790	0	Form 4
2025-08-14	Aggarwal Sumit	director	Option exercise	60,390	0	Form 4
2025-08-14	Aggarwal Sumit	director	Option exercise	68,700	0	Form 4
2025-08-14	Aggarwal Sumit	director	Option exercise	25,000	0	Form 4
2025-01-24	Androski Lindsay	director	Option exercise	3,750	15,750	Form 4
2025-01-24	Rubin Steven D	director	Option exercise	3,750	3,750	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

27d remaining

2026-09-2610% elapsed2026-10-26

Logged immutably 2026-09-26; scored automatically on 2026-10-26 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Pending catalysts

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i